Zentalis Pharmaceuticals
ZNTL
137 hedge funds and large institutions have $1.61B invested in Zentalis Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 52 increasing their positions, 39 reducing their positions, and 13 closing their positions.
431% more call options, than puts
Call options by funds: $4.81M | Put options by funds: $906K
33% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 39
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
2% more funds holding
Funds holding: 134 → 137 (+3)
3.37% less ownership
Funds ownership: 116.94% → 113.58% (-3.4%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
31% less capital invested
Capital invested by funds: $2.32B → $1.61B (-$715M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$23.8M |
| 2 |
BlackRock
New York
|
+$11.3M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$9.74M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.8M |
| 5 |
Millennium Management
New York
|
+$6.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$32.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.5M |
| 3 |
Goldman Sachs
New York
|
-$13M |
| 4 |
State Street
Boston,
Massachusetts
|
-$11.4M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$10M |
ZNTL Hedge Fund Activity: Q3 2023 in Review
137 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q3 2023, worth a combined $1.61B — down 31% from $2.32B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ZNTL positions and 13 closed out — a net gain of 4 holders — while 52 added to existing stakes and 39 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $23.8M. The largest seller was AllianceBernstein, cutting an estimated $32.1M.
- 137 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q3 2023, up from 134 in Q2 2023.
- Funds reported $1.61B of Zentalis Pharmaceuticals stock for Q3 2023, down 31% quarter-over-quarter.
- 17 funds opened new Zentalis Pharmaceuticals positions in Q3 2023 and 13 closed out, a net change of +4 holders.
- The largest Zentalis Pharmaceuticals buyer in Q3 2023 was Eventide Asset Management, an estimated $23.8M added.
- The largest Zentalis Pharmaceuticals seller in Q3 2023 was AllianceBernstein, an estimated $32.1M sold.
Based on aggregated 13F filings for Q3 2023.